Cambridge Innovation Capital and Amadeus Capital Partners led the seed round to support quantum software development.
"This seed funding allows us to accelerate our work at a critical time in the development of quantum computers. Computers are central to the design of many new products, but when we try to model systems at the level of individual atoms, the rules that govern their behaviour are fundamentally different. Even huge supercomputers are limited to approximations. As a result the design of new drugs and materials remains primarily a laboratory, rather than a computational, exercise. Riverlane’s software aims to unleash the huge potential of quantum computers."
The funding round was led by Cambridge Enterprise with participation from Amadeus Capital Partners, Parkwalk Advisors, IQ Capital Partners and angel investors.
"The new Paragraf facility is a significant step towards realising the potential of graphene in commercially viable, scalable electronic devices, bringing the beneficial impacts of this wonder material to the world."
The follow-on investment will fund the commercial launch of new pancreatic and lung stem cell products.
"In a short space of time, DefiniGEN has undergone rapid development, securing growing sales with global pharma companies. We are delighted to have raised the funds that will allow us to deliver new market-leading products to our customers and assist them in developing therapies for the global healthcare challenges we face today such as diabetes and liver disease."
